Strategies for Continued IRT Success During COVID-19 Date Published: Jun 24, 2020 Article Featured in Journal for Clinical Studies, this article discusses the challenges IRT customers face with the recent COVID-19 pandemic and how to mitigate these potential issues to avoid interrupting ongoing clinical trials. Discover best practices for: Distribution challengesScreening & enrollment challengesA properly configured and adaptive IRT system can enable organizations to remain flexible and agile enough to face any challenge. Signant Health’s team of IRT designers, developers, supply experts, and statisticians are available to consult on challenges and best practices. Download Now Share: LinkedIn0Tweet0 Recommended Resources Article The Changing Face of Oncology Endpoint Monitoring Historically, endpoints in oncology clinical trials centered on tumor response, but approach alone fails to take into account how well... Download Now Article How to Make Translations Work for Everyone Many clinical trials today require access to global participant populations, increasing demand for accurate translations and localization of all study... Read Article Article Moving Beyond the Spreadsheet: How to Forecast & Plan Enterprise Supply Needs Without precise forecasting and planning tools, sponsors often send sites so much stock that it makes it difficult and time consuming for study teams... Download Now